A new strategy controlling of AKT-mTOR pathway with targeting to progression of castration resistant prostate cancer.
Project/Area Number |
23791787
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | Keio University |
Principal Investigator |
YASUMIZU Yota 慶應義塾大学, 医学部, 助教 (40464854)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 去勢抵抗性前立腺癌 / PI3K/AKT/mTOR pathway / ドセタキセル抵抗性 / Dual PI3K/mTORC1/2阻害剤 / PI3K-Akt-mTOR シグナル伝達 / PI3K・mTORC1/2阻害剤 / 前立腺癌 / 去勢抵抗性 / PI3K-Aktシグナル伝達 |
Research Abstract |
In this study we explored the efficacy of a AKT-mTOR pathway inhibitor for docetaxel resistant prostate cancer cell line: C4-2AT6. C4-2AT6 cells revealed combined administration of AKT-mTOR pathway inhibitor and docetaxel had a significant and synergistic
|
Report
(3 results)
Research Products
(11 results)